Renin Inhibition Improves the Survival of Mesenchymal Stromal Cells in a Mouse Model of Myocardial Infarction

Franchi, Federico; Ezenekwe, Adachukwu; Wellkamp, Lukas; Peterson, Karen M.; Lerman, Amir; Rodriguez-Porcel, Martin

doi:10.1007/s12265-014-9575-3

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs were isolated from mice (friend virus B-type (FVB) background) and characterized as previously described [33, 34]. MSCs were, then, challenged with increasing doses of diethylmaleate (DEM, 50–150 μM), a known mitochondrial stressor [35–37].…”

Section: Methodsmentioning

confidence: 99%

Noninvasive Monitoring of the Mitochondrial Function in Mesenchymal Stromal Cells

et al. 2016

Self Cite

View full text Add to dashboard Cite

Purpose Mitochondria are a gatekeeper of cell survival and mitochondrial function can be used to monitor cell stress. Here we validate a pathway-specific reporter gene to noninvasively image the mitochondrial function of stem cells. Procedures We constructed a mitochondrial sensor with the firefly luciferase (Fluc) reporter gene driven by the NQO1 enzyme promoter. The sensor was introduced in stem cells and validated in vitro and in vivo, in a mouse model of myocardial ischemia/reperfusion (IR). Results The sensor activity showed an inverse relationship with mitochondrial function (R2 = −0.975, p = 0.025) and showed specificity and sensitivity for mitochondrial dysfunction. In vivo, NQO1-Fluc activity was significantly higher in IR animals vs. controls, indicative of mitochondrial dysfunction, and was corroborated by ex vivo luminometry. Conclusions Reporter gene imaging allows assessment of the biology of transplanted mesenchymal stromal cells (MSCs), providing important information that can be used to improve the phenotype and survival of transplanted stem cells.

show abstract

Section: Methodsmentioning

confidence: 99%

Noninvasive Monitoring of the Mitochondrial Function in Mesenchymal Stromal Cells

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Currently, early pre-clinical in vivo models provide information on po-tential future patents. Inhibition of the Renin pathway [26] protection by enhancement of the pro-angiogenic receptor Notch 1 [27], and overexpression of myocardin, a transcrip-tion co-activator [28] are all approaches adapting the host en-vironment to potentiate the effect of the stem cells. Other tac-tics consider modifying the progenitor cells themselves.…”

Section: Pre-clinical Stem Cells Therapy To Treat Myocardial Infarctionmentioning

confidence: 99%

Stem Cell Therapies for Ischemic Cardiovascular Diseases

Murdoch

Broadway-Stringer

Bartkeviciute

et al. 2015

RPGM

View full text Add to dashboard Cite

Myocardial infarction results in loss of cardiac muscle and deficiency in cardiac performance. Likewise, peripheral\ud artery disease can result in critical limb ischemia leading to reduced mobility, non-healing ulcers, gangrene and\ud amputation. Both of these common conditions diminish quality of life and enhance risk of mortality. Successful advances\ud in treatment have led to more people surviving incidences of myocardial infarction or living with peripheral artery disease.\ud However, the current treatments are inadequate in repairing ischemic tissue. Over the last 5 years, a vast number of patents\ud have been submitted concerning the use of stem cells, which correlates with the exponential growth in stem cell publications.\ud Exploiting stem cell therapy offers a real potential in replacing ischemic tissue with functional cells. In this paper,\ud we review recent patents concerning stem cell therapy that have the potential to provide or potentiate novel treatment\ud for ischemic cardiovascular disease. In addition, we evaluate the promise of the inventions by describing some clinical trials\ud that are currently taking place, as well as considering how current research on ischemic cardiovascular disease may\ud change the patent landscape in the future

show abstract

“…During the last ten years, using a reporter gene strategies designed to express the firefly luciferase (Fluc) or renilla luciferase (Rluc) gene, Bioluminescence Imaging (BLI) has been successfully adopted to monitor in vivo stem cell viability and engraftment[29,18,30] as well as to study transplanted stem cell biology and its interaction with the microenvironment[28] (Figure 1). Due to the lack of spatial resolution and tissue depth penetration, the use of BLI is restricted to small animal studies (rats and mice)[26].…”

Section: Introductionmentioning

confidence: 99%

Noninvasive Assessment of Cell Fate and Biology in Transplanted Mesenchymal Stem Cells

Franchi

Rodriguez-Porcel

2017

Adult Stem Cells

Self Cite

View full text Add to dashboard Cite

Summary Recently, molecular imaging has become a conditio sine qua non for cell-based regenerative medicine. Developments in molecular imaging techniques, such as reporter gene technology, have increasingly enabled the noninvasive assessment of the fate and biology of cells after cardiovascular applications. In this context, bioluminescence imaging is the most commonly used imaging modality in small animal models of preclinical studies. Here, we present a detailed protocol of a reporter gene imaging approach for monitoring the viability and biology of Mesenchymal Stem Cells transplanted in a mouse model of myocardial ischemia reperfusion injury.

show abstract

Renin Inhibition Improves the Survival of Mesenchymal Stromal Cells in a Mouse Model of Myocardial Infarction

Cited by 7 publications

References 29 publications

Noninvasive Monitoring of the Mitochondrial Function in Mesenchymal Stromal Cells

Noninvasive Monitoring of the Mitochondrial Function in Mesenchymal Stromal Cells

Stem Cell Therapies for Ischemic Cardiovascular Diseases

Noninvasive Assessment of Cell Fate and Biology in Transplanted Mesenchymal Stem Cells

Contact Info

Product

Resources

About